Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.

Publication

Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.

Journal Paper/Review - Apr 15, 2022

Rüfenacht Susanne, Gantenbein Pascal, Boggian Katia, Flury Domenica, Kern Lukas, Dollenmaier Günter, Kohler Philipp, Albrich Werner

Citation

Rüfenacht S, Gantenbein P, Boggian K, Flury D, Kern L, Dollenmaier G, Kohler P, Albrich W. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series. Infection 2022; 50:783-790.

Type

Journal Paper/Review (English)

Journal

Infection 2022; 50

Publication Date

Apr 15, 2022

Issn Electronic

1439-0973

Pages

783-790

Brief description/objective

COVID-19 patients on anti-CD20 treatment can suffer a delayed viral clearance and worse clinical outcome. We aim to present our experience with remdesivir treatment in anti-CD20-treated patients with prolonged symptoms, a patient population for which no data from randomized controlled trials are available.